Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)
Gaetano Bergamaschi,Fabiana Castiglione,Renata D'Incà,Marco Astegiano,Walter Fries,Monica Milla,Carolina Ciacci,Fernando Rizzello,Simone Saibeni,Rachele Ciccocioppo,Ambrogio Orlando,Fabrizio Bossa,Mariabeatrice Principi,Piero Vernia,Chiara Ricci,Maria L. Scribano,Giorgia Bodini,Dario Mazzucco,Gabrio Bassotti,Gabriele Riegler,Andrea Buda,Matteo Neri,Flavio Caprioli,Fabio Monica,Aldo Manca,Erica Villa,Gionata Fiorino,Nicola Aronico,Marco V. Lenti,Caterina Mengoli,Anna Testa,Maurizio Vecchi,Catherine Klersy,Antonio Di Sabatino,RIDART I investigators,Giuseppe Amodeo,Elisabetta Antonelli,Noemi Bertetti,Cristina Bezzio,Michele Campigotto,Roberta Caccaro,Manuela De Bona,Cristina Della Corte,Maria G. Demarzo,Giuliano Falasco,Rosanna Fontana,Paolo Gionchetti,Paola Iovino,Federica Lepore,Greta Lorenzon,Veronica Marasco,Alessandro Paolini,Lucienne Pellegrini,Alberto Pieraccini,Tiziana Pinto-Vraca,Davide Ribaldone,Giulia Rizzuto,Jenny Roselli,Giovanni Santacroce,Alessia Todeschini,Marta Vernero,Anna Viola,Irene Zammarchi
DOI: https://doi.org/10.1016/j.dld.2024.01.176
IF: 5.165
2024-01-01
Digestive and Liver Disease
Abstract:BACKGROUND: The RIDART I study found a 13.6% prevalence of anemia in Italian patients with inflammatory bowel disease (IBD); most cases were due to iron-deficiency anemia (IDA).AIMS: To evaluate changes in hemoglobin concentration during a 24-week follow-up of anemic patients with IBD.METHODS: Follow-up laboratory and clinical data were obtained from RIDART I study patients with anemia. Factors affecting hemoglobin concentration, the impact of anemia on fatigue and quality of life (QoL), and its relationship with treatment, disease activity and disease complications were investigated.RESULTS: Hemoglobin was 108 g/L at baseline, increased to 121 g/L at follow-up week 12 (p < 0.001) and then stabilized until week 24, but most patients remained anemic, with IDA, throughout the study. Hemoglobin improvement was greater in patients receiving either oral or parenteral iron supplementation. Following hemoglobin normalization, anemia relapse rate during follow-up was 30%. Oral iron did not cause disease reactivation. Lower follow-up hemoglobin was associated with a higher probability of having active disease, clinical complications, increased fatigue and reduced QoL.CONCLUSIONS: In anemic patients with IBD, anemia represents a long-lasting problem, in most cases persisting for up to 24 weeks, with high relapse rate and a negative impact on fatigue and QoL.
gastroenterology & hepatology